Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29362450 | 0.92 | ESR1 (0.69) | ESR1ESR2 | |
| SCHEMBL6669000 | 0.92 | ESR1 (0.69) | ESR1ESR2 | |
| SCHEMBL7943653 | 0.90 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL8486984 | 0.90 | ESR1 (0.68) | ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL8429229 | 0.90 | ESR1 (0.98) | ESR1ESR2 | |
| SCHEMBL9153745 | 0.89 | ESR1 (0.98) | ESR1ESR2 | |
| SCHEMBL30076531 | 0.89 | ESR1 (0.89) | ESR1ESR2 | |
| SCHEMBL9152189 | 0.86 | ESR1 (0.84) | ESR1ESR2 | |
| SCHEMBL8848751 | 0.82 | ESR1 (0.56) | ESR1ESR2 | |
| SCHEMBL7941540 | 0.81 | ESR1 (0.71) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010051636-A1 | Combination treatment for inhibiting bone loss | BLACK LARRY J (US) | 2001-12-13 | — | — | US | claimed |
| WO-1999002512-A1 | DL-2,3-DIARYL-2H-1-BENZOPYRANS | NOVO NORDISK A/S (DK) | 1999-01-21 | — | — | WO | claimed |
| EP-0470310-B1 | Novel benzopyrans and process for their production | COUNCIL SCIENT IND RES (IN) | 1995-11-29 | — | — | EP | claimed |
| US-5446061-A | Administering 2-phenyl-3-aryl-dihydrobenzopyran derivatives | ELI LILLY AND COMPANY (US) | 1995-08-29 | — | — | US | claimed |
| EP-0652007-A1 | Use of 2-phenyl-3-aryl-dihydrobenzopyrans for inhibiting bone loss | ELI LILLY AND COMPANY (US) | 1995-05-10 | — | — | EP | claimed |
| EP-0652006-A1 | Use of 2-phenyl-3-aryl-dihychobenzopyrans for lowering serum cholesterol | ELI LILLY AND COMPANY (US) | 1995-05-10 | — | — | EP | claimed |
| US-5407947-A | Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans | ELI LILLY AND COMPANY (US) | 1995-04-18 | — | — | US | claimed |
| US-5254568-A | Benzopyrans as antiestrogenic agents | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 1993-10-19 | — | — | US | claimed |
| EP-0470310-A1 | Novel benzopyrans and process for their production | Council of Scientific and Industrial Research (IN) | 1992-02-12 | — | — | EP | claimed |
| US-20010051636-A1 | Combination treatment for inhibiting bone loss | BLACK LARRY J (US) | 2001-12-13 | — | — | US | disclosed |
| WO-1999002512-A1 | DL-2,3-DIARYL-2H-1-BENZOPYRANS | NOVO NORDISK A/S (DK) | 1999-01-21 | — | — | WO | disclosed |
| US-5567713-A | ADMINISTERING (6-HYDROXY-2-(4-HYDROXYPHENYL)BENZO(B)THIEN-3-YL)(4-(2-(1-(PIPERIDINYL OR PYRROLIDINYL)ETHOXY)PHENYL) METHANONE TO MAMMAL | ELI LILLY AND COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| EP-0693285-A2 | Pharmaceutical compositions containing a bisphosphonate and an anti-resorptive agent for inhibiting bone loss | ELI LILLY AND COMPANY (US) | 1996-01-24 | — | — | EP | disclosed |
| EP-0470310-B1 | Novel benzopyrans and process for their production | COUNCIL SCIENT IND RES (IN) | 1995-11-29 | — | — | EP | disclosed |
| EP-0652007-A1 | Use of 2-phenyl-3-aryl-dihydrobenzopyrans for inhibiting bone loss | ELI LILLY AND COMPANY (US) | 1995-05-10 | — | — | EP | disclosed |
| EP-0652006-A1 | Use of 2-phenyl-3-aryl-dihychobenzopyrans for lowering serum cholesterol | ELI LILLY AND COMPANY (US) | 1995-05-10 | — | — | EP | disclosed |
| US-5407947-A | Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans | ELI LILLY AND COMPANY (US) | 1995-04-18 | — | — | US | disclosed |
| EP-0635264-A2 | Antiestrogens as hypoglycemic agents | ELI LILLY AND COMPANY (US) | 1995-01-25 | — | — | EP | disclosed |
| US-5254568-A | Benzopyrans as antiestrogenic agents | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 1993-10-19 | — | — | US | disclosed |
| EP-0470310-A1 | Novel benzopyrans and process for their production | Council of Scientific and Industrial Research (IN) | 1992-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051636-A1 | Combination treatment for inhibiting bone loss | SOST, BMP2, PTH1R | ESR1 922/4885ESR2 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.